8 IPOs Just Got SEBI’s Green Light: Your 2026 Investment Radar

Updated as of August 22, 2026

While most of India was celebrating New Year, SEBI quietly approved eight major IPOs worth thousands of crores between December 26 and January 2 — a diverse lineup spanning fertility clinics to fitness equipment, signaling a robust start to 2026’s primary market season.

Eight months on, the picture has clarified considerably. Some of these names are already trading or about to open for subscription; others are still sitting on approvals that expire within their 12–18 month window. Here’s where every one of them stands today, plus a look at the mega-cap IPOs — NSE, Jio, OYO, Zepto, boAt, Acko, and MakeMyTrip — that are shaping the broader 2026 primary market narrative.

The Original Eight: Where They Stand Now

SEBI’s approval is the starting gun, not the finish line. Of the eight companies cleared in that late-December batch, only two have actually made it to market so far.

A) Tempsens Instruments IPO — 🟢 Live and trading soon. This Rajasthan-based thermal engineering and specialised-cable manufacturer is the standout mover of the batch. Its ₹650 crore book-built issue (₹95 cr fresh issue + ₹555 cr OFS) opened August 20 and closed August 24, price band ₹285–300/share. Allotment finalizes August 25, with listing tentatively set for August 28 on BSE/NSE. Grey Market Premium ran hot in the days before close — reported anywhere from ₹175 to ₹274 over the upper band — implying strong retail appetite, though GMP is an unofficial indicator and often diverges from actual listing performance.

B) Rays Of Belief IPO (Mom’s Belief) — 🟢 Firm dates, opening next. The child-development and therapy platform behind the Mom’s Belief brand has locked in its schedule: IPO opens September 1, closes September 3, with listing tentatively September 8. It’s a 100% fresh issue of ~52.3 lakh shares (no OFS), expected to raise roughly ₹149–152 crore based on pre-IPO placement pricing. FY26 revenue grew 125%, though profit dipped ~16% to ₹4.95 crore — a familiar growth-over-profitability trade-off for a scaling healthcare business. Anchor bidding is set for August 31.

C) Jerai Fitness IPO — 🟡 Still TBA. SEBI approved this pure-OFS gym-equipment exit back on January 2 (approval valid 12 months), but price band, lot size, and open/close dates remain unannounced eight months later. The structure hasn’t changed: 43.92 lakh shares, entirely promoters (Rajesh Ramsukh Rai, Rinku Rajesh Rai, and family HUF) cashing out, zero fresh capital to the company.

D) Glass Wall Systems IPO (India) — 🟡 Also approved (December 29) but undated. The façade and fenestration specialist’s ₹60 crore fresh issue plus ~4.02 crore share OFS is confirmed — India Business Excellence Fund remains among the exiting investors — but price band and dates are still pending.

E) Chartered Speed IPO — 🟡 Gujarat’s passenger-mobility play, approved January 2, remains undated. The ₹855 crore structure (₹655 cr fresh + ₹200 cr OFS) to expand its 2,000+ bus fleet and cut debt is unchanged, but open/close dates and price band haven’t surfaced.

F) Shriram Food Industry IPO — 🟡 Similarly undated. The Nagpur-based rice exporter’s ~2.64 crore share issue (₹212 cr fresh + 52 lakh shares OFS by promoters) is still waiting on its price band.

G) Indira IVF IPO — 🟡 EQT-backed and eyeing what could be the year’s biggest healthcare debut at a reported ₹3,500 crore. Filed via the confidential route (giving it an 18-month runway instead of 12), which suggests the company is timing its launch carefully rather than rushing to market. No public dates yet.

H) RKCPL IPO — 🟡 Leads the batch by headline size: a ₹1,250 crore infrastructure and construction-services offering (₹700 cr fresh issue + ₹550 cr OFS). Approved in the same window, still awaiting its price band and launch dates.

Where the batch stands today

The Mega-Caps Shaping 2026’s Narrative

Beyond this original batch, seven much larger names are defining the broader IPO conversation this year — and their trajectories look very different from each other.

A) NSE IPO (National Stock Exchange) — 🔵 Closest to the finish line among the mega-caps. Filed its DRHP on June 17 for a 6% OFS of ~14.89 crore shares, potentially India’s largest-ever IPO (street estimates ₹28,000–30,000 crore, valuation ₹4.85–5.26 lakh crore). SEBI gave an in-principle NOC in January and accepted revised settlement terms on July 30 (NSE paid ~₹715 crore toward settling co-location-era matters). SEBI observations on the DRHP are expected by mid-August, with a September 2026 listing widely targeted — though this timeline has slipped repeatedly over NSE’s near-decade-long path to market, so treat it as directional, not locked.

B) Reliance Jio IPO (Jio Platforms) — 🔵 DRHP filed June 19 — a 100% fresh issue of 27 crore shares, no OFS, aimed largely at debt repayment (₹27,500 cr) and AI/digital infrastructure investment. Listing window guided at August–October 2026, with valuation talk ranging $112–180 billion. Existing RIL shareholders and Jio employees get a reserved quota. Still pending SEBI’s observations.

C) OYO IPO (parent renamed PRISM, formerly Oravel Stays) — 🟢 Furthest along of the “new economy” names. SEBI cleared it June 5; updated DRHP filed June 30 for a ₹6,650 crore 100% fresh issue (no OFS), with ~75% earmarked for debt repayment at its Singapore subsidiary. FY26 nine-month profit tripled to ₹748 crore. Listing is being targeted for the August–September 2026 window, though the price band isn’t out yet — a possible pre-IPO placement of up to ₹1,330 crore could shrink the final public issue size.

D) Zepto IPO — 🔴 Postponed — the key development among the mega-caps. After filing an updated DRHP on June 9 (₹8,010 cr fresh issue + OFS of 11.35 crore shares, ~$850M target), CEO Aadit Palicha told employees on August 1 that the IPO is being pushed back roughly two to three quarters — likely into 2027. FY26 revenue doubled to ₹22,623 crore, but losses also widened to ₹5,905 crore, and there’s an unresolved FEMA compliance matter involving the founders under ED scrutiny.

E) boAt IPO (Imagine Marketing) — 🟡 Updated DRHP is in with SEBI (~₹1,500 crore: ₹500 cr fresh issue + ₹1,000 cr OFS); founders Aman Gupta and Sameer Mehta remain promoters holding ~89%. Some trackers pencil in a late September 2026 window (tentatively Sep 27–29) with October listing, but SEBI approval and official dates aren’t confirmed — treat these as speculative estimates.

F) Acko Insurance IPO — 🟠 Earliest-stage of this group. Investment banks (Kotak, ICICI Securities, Morgan Stanley) are appointed, targeting $250–350 million at a $2–2.5 billion valuation. Confidential DRHP filing is planned for 2026, with listing pushed to 2027. Its insurance subsidiary turned profitable in FY26 (₹43.6 cr profit vs ₹193 cr loss in FY25) — an encouraging signal heading into the process.

G) MakeMyTrip IPO (India) — 🟢 MMT’s India subsidiary confidentially filed its DRHP on July 17, targeting over $1 billion via a pure OFS by parent MakeMyTrip and Singapore-based ibibo — meaning no fresh capital flows to the India business itself. This would be a dual listing alongside its existing Nasdaq listing, aimed at BSE and NSE, though no date is set yet.

Mega-cap snapshot

5 Things Smart Investors Should Know Right Now

1. Timeline matters. SEBI approvals are typically valid 12–18 months — track RHP filings, not just DRHP news, since a cleared IPO can still quietly lapse if it never launches.
2. Pure OFS deals mean zero dilution but full promoter/investor exit. Jerai Fitness, NSE, and MakeMyTrip India all fall in this bucket — no fresh capital reaches the underlying business.
3. Fresh-issue IPOs fuel growth or delever balance sheets — watch the stated use of proceeds closely. Jio and OYO are both using the bulk of their raise for debt repayment, not expansion.
4. Sector diversity spreads risk across infrastructure, healthcare, manufacturing, and consumer tech — but timelines within a single batch can diverge wildly, as Tempsens (live now) versus Jerai Fitness (still undated) shows.
5. Confidential-route filers buy themselves flexibility. Indira IVF, Rays Of Belief, Zepto, Acko, and MakeMyTrip India all used or are using this route — it lets a company wait for better market conditions before locking in a price band, which cuts both ways for investors trying to time an entry.

The Bottom Line

Eight original approvals, two now live or imminent, six still waiting on dates. Layer in seven mega-cap names worth a combined tens of billions of dollars, and 2026’s IPO calendar is unusually front-loaded with headline risk and headline opportunity in the same breath.

Your move: Track RHP filings as they land, read the financials the moment they’re public, and don’t mistake a SEBI approval — or a banker’s “targeted window” — for a locked listing date. Zepto’s postponement is the clearest reminder this year that even a filed, approved IPO can move by quarters, not days.

Share this with your investing group—someone’s looking for 2026’s hidden gems right now.

Investment Disclaimer (as per SEBI guidelines)

The information provided in this article is for educational and informational purposes only and should not be construed as investment advice, trading recommendation, or solicitation to buy or sell any securities, commodities, derivatives, or financial instruments.

Investments in the stock market and commodity markets (including gold and silver futures) are subject to market risks, including price volatility, liquidity risk, and regulatory risk. Past performance is not indicative of future results.

Readers are advised to conduct their own research and/or consult a SEBI-registered investment adviser, research analyst, or financial professional before making any investment or trading decisions. The author and publisher are not registered as SEBI investment advisers or research analysts, unless explicitly stated otherwise, and shall not be responsible for any financial losses incurred based on the information presented.

Commodity derivatives trading involves high leverage and risk of substantial loss and may not be suitable for all investors. Please carefully consider your financial situation, risk appetite, and investment objectives before participating.

SEBI Registration, if applicable, should be verified on the official SEBI website.

Source

Mayank Srivastava

Mayank Srivastava is a Indian Stock Market Expert with over 2+ years of experience in financial markets and investment analysis. He specializes in IPO evaluations, grey market premium tracking,various stock market strategies, derivatives strategies and data-driven investment research.

His analysis has helped thousands of retail investors make informed decisions in the Indian primary market. Mayank holds advanced certifications in financial Market and regularly contributes to leading financial publications. But he is not SEBI registered Finance Professional. He writes only for educational purpose not giving any investment advice. Please Consult SEBI Registered Finance Consultant or Professional before any investment in stock market. He is not responsible any investment loss after reading this website content